Javascript must be enabled to continue!
METTL3 mediated m6A methylation of HIF-1 α promoted progression in glioma
View through CrossRef
Abstract
Background
Glioma was a malignant tumor of the central nervous system. m6A methylation and HIF-1α were related to the occurrence and development of gliomas. However, the co-mechanism of m6A methylation and HIF-1α in glioma is unclear.
Objective
This aim was to determine the m6A methylation of HIF-1α in glioma.
Methods
Elisa and dot blot were used to detect m6A level. The changes of related genes, biological pathways and gene ontology were analyzed by bioinformatics. METTL3 and HIF-1α were knockdown by sh-RNA, and the mRNA and protein level were detected by qPCR and western blot. In addition, the m6A RNA methylation sites were predicted and verified by m6A-RIP-MMP-6 analysis༎
Results
We found that compared with paracancerous, the mRNA and protein levels of m6A were dramatically increased in glioma. The biological different were found in glioma and paracancerous. Moreover, glioma had highly mRNA and protein level of HIF-1α. METTL3 and HIF- 1α knockdown can significantly decrease the growth of glioma cells. Furthermore, we confirmed the m6A RNA methylation site in HIF-1α. Finally, we found that METTL3 regulated the m6A level and RNA stability of HIF-1α.
Conclusion
Our finding demonstrated that the co-mechanism of m6A methylation of HIF-1α and METTL3 in glioma, and may be helpful in the treatment of glioma.
Title: METTL3 mediated m6A methylation of HIF-1 α promoted progression in glioma
Description:
Abstract
Background
Glioma was a malignant tumor of the central nervous system.
m6A methylation and HIF-1α were related to the occurrence and development of gliomas.
However, the co-mechanism of m6A methylation and HIF-1α in glioma is unclear.
Objective
This aim was to determine the m6A methylation of HIF-1α in glioma.
Methods
Elisa and dot blot were used to detect m6A level.
The changes of related genes, biological pathways and gene ontology were analyzed by bioinformatics.
METTL3 and HIF-1α were knockdown by sh-RNA, and the mRNA and protein level were detected by qPCR and western blot.
In addition, the m6A RNA methylation sites were predicted and verified by m6A-RIP-MMP-6 analysis༎
Results
We found that compared with paracancerous, the mRNA and protein levels of m6A were dramatically increased in glioma.
The biological different were found in glioma and paracancerous.
Moreover, glioma had highly mRNA and protein level of HIF-1α.
METTL3 and HIF- 1α knockdown can significantly decrease the growth of glioma cells.
Furthermore, we confirmed the m6A RNA methylation site in HIF-1α.
Finally, we found that METTL3 regulated the m6A level and RNA stability of HIF-1α.
Conclusion
Our finding demonstrated that the co-mechanism of m6A methylation of HIF-1α and METTL3 in glioma, and may be helpful in the treatment of glioma.
Related Results
Abstract 5961: The roles of METTL3 in colorectal cancer
Abstract 5961: The roles of METTL3 in colorectal cancer
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, accounting for 10% of all cancer deaths. Metastatic disease occurs in h...
P1621m6A RNA-methylation in the progression of heart failure
P1621m6A RNA-methylation in the progression of heart failure
Abstract
Introduction
N6-Methyladenosine (m6A) is the most abundant modification of RNA and was found to be a dynamic and revers...
Abstract 1737: METTL3-mediated m6A modification promotes tumor progression in upper tract urothelial carcinoma
Abstract 1737: METTL3-mediated m6A modification promotes tumor progression in upper tract urothelial carcinoma
Abstract
Upper tract urothelial carcinoma (UTUC), comprising 5% of urothelial neoplasms, is a rare malignancy arising from the transitional epithelium of the renal p...
METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner
METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner
Acquired chemoresistance is a major limiting factor in the clinical treatment of glioblastoma (GBM). However, the mechanism by which GBM acquires therapeutic resistance remains unc...
The m6A Methyltransferase METTL3 Promotes Cisplatin Resistance and Invasion in Testicular Seminoma via BCL2
The m6A Methyltransferase METTL3 Promotes Cisplatin Resistance and Invasion in Testicular Seminoma via BCL2
Abstract
Background: Methyltransferase-like 3 (METTL3) involves in promoting tumor progression through tumor-related genes N6-methyladenosine (m6A) modification. Our previo...
METTL3 shapes m6A epitranscriptomic landscape for successful human placentation
METTL3 shapes m6A epitranscriptomic landscape for successful human placentation
Abstract
Methyltransferase-like 3 (METTL3), the catalytic enzyme of methyltransferase complex for m6A methylation of RNA, is essential for mammal...
Structural dynamics of m6A formation in mRNA
Structural dynamics of m6A formation in mRNA
N6-Methyladenosin (m6A) ist die häufigste Modifikation in eukaryotischer mRNA. Der menschliche N6-Methyltransferasekomplex (MTC) methyliert cotranskriptionell das zentrale Adenin i...
N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma
N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma
Background: N6-methyladenosine (m6A) modification is a part of epigenetic research that has gained increasing attention in recent years. m6A modification is widely involved in many...

